SCHEMBL2158126

SCHEMBL2158126

CN(C(=O)CCC1CCCC1)c1csc(-c2ccccc2)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.42
RAB9A P51151 3/20 0.42
ALDH1A1 P00352 4/20 0.41
HTT P42858 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
HTR5A P47898 3/20 0.41
SLC6A4 P31645 2/20 0.41
MEN1 O00255 6/20 0.40
KMT2A Q03164 6/20 0.40
TDP1 Q9NUW8 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.39
OPRM1 P35372 1/20 0.39
OPRL1 P41146 1/20 0.39
HPGD P15428 2/20 0.38
MAPT P10636 2/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
HTR1A P08908 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2158566 0.86 ALDH1A1 (0.40) NPC1RAB9AALDH1A1HTTNPSR1
SCHEMBL4067619 0.80 PKM (0.52) NPC1RAB9AALDH1A1HTTNPSR1
SCHEMBL2158507 0.79 FASN (0.43) NPC1RAB9AHSD17B1HSD17B2LMNA
SCHEMBL2158434 0.78 FASN (0.42) NPC1RAB9ANPSR1HSD17B1HSD17B2
SCHEMBL6427124 0.77 NPC1 (0.40) NPC1RAB9AALDH1A1HTTNPSR1
SCHEMBL3817549 0.76 NPC1 (0.39) NPC1RAB9AALDH1A1HTTNPSR1
SCHEMBL2157858 0.75 TACR1 (0.40) NPC1RAB9AALDH1A1HTTNPSR1
SCHEMBL2157762 0.74 LTB4R2 (0.48) NPC1RAB9AALDH1A1HTTNPSR1
SCHEMBL2157776 0.72 IDE (0.36) NPC1RAB9AALDH1A1HTTMEN1
SCHEMBL2157917 0.71 HTT (0.43) ALDH1A1HTTMEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7985769-B2 Compounds and methods for the treatment or prevention of Flavivirus infections VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-07-26 US disclosed
US-20060142347-A1 Compounds and methods for the treatment or prevention of Flavivirus infections VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) 2006-06-29 US disclosed
US-6881741-B2 Compounds and methods for the treatment or prevention of Flavivirus infections VIROCHEM PHARMA INC. (CA) 2005-04-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060142347-A1 Compounds and methods for the treatment or prevention of Flavivirus infections HAVCR2, ZC3HAV1, MAVS NPC1 30/4885RAB9A 1333/4885ALDH1A1 684/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.